CO2017002166A2 - Proteínas de fusión de interleucina 2 / receptor de interleucina-2 alfa - Google Patents

Proteínas de fusión de interleucina 2 / receptor de interleucina-2 alfa

Info

Publication number
CO2017002166A2
CO2017002166A2 CONC2017/0002166A CO2017002166A CO2017002166A2 CO 2017002166 A2 CO2017002166 A2 CO 2017002166A2 CO 2017002166 A CO2017002166 A CO 2017002166A CO 2017002166 A2 CO2017002166 A2 CO 2017002166A2
Authority
CO
Colombia
Prior art keywords
interleukin
polypeptide
fusion protein
fusion proteins
alpha receptor
Prior art date
Application number
CONC2017/0002166A
Other languages
English (en)
Spanish (es)
Inventor
Thomas Malek
Original Assignee
Univ Miami
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53836871&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO2017002166(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Miami filed Critical Univ Miami
Publication of CO2017002166A2 publication Critical patent/CO2017002166A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
CONC2017/0002166A 2014-08-06 2017-03-03 Proteínas de fusión de interleucina 2 / receptor de interleucina-2 alfa CO2017002166A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462033726P 2014-08-06 2014-08-06
PCT/US2015/043792 WO2016022671A1 (en) 2014-08-06 2015-08-05 Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use

Publications (1)

Publication Number Publication Date
CO2017002166A2 true CO2017002166A2 (es) 2017-05-19

Family

ID=53836871

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2017/0002166A CO2017002166A2 (es) 2014-08-06 2017-03-03 Proteínas de fusión de interleucina 2 / receptor de interleucina-2 alfa

Country Status (32)

Country Link
US (3) US12084483B2 (https=)
EP (2) EP4438621A3 (https=)
JP (3) JP6723982B2 (https=)
KR (1) KR102653758B1 (https=)
CN (2) CN107074967B (https=)
AU (3) AU2015301071C1 (https=)
BR (1) BR112017001940A2 (https=)
CA (1) CA2957273C (https=)
CL (1) CL2017000284A1 (https=)
CO (1) CO2017002166A2 (https=)
DK (1) DK3177307T3 (https=)
EA (2) EA202091342A3 (https=)
ES (1) ES2986097T3 (https=)
FI (1) FI3177307T3 (https=)
HR (1) HRP20241258T1 (https=)
HU (1) HUE068478T2 (https=)
IL (2) IL250007B (https=)
LT (1) LT3177307T (https=)
MA (2) MA40094B1 (https=)
MX (1) MX388977B (https=)
MY (1) MY180831A (https=)
PE (1) PE20170503A1 (https=)
PH (1) PH12017500042A1 (https=)
PT (1) PT3177307T (https=)
RS (1) RS65930B1 (https=)
SA (1) SA517380842B1 (https=)
SG (2) SG10201913695PA (https=)
SI (1) SI3177307T1 (https=)
SM (1) SMT202400414T1 (https=)
TN (1) TN2017000020A1 (https=)
WO (1) WO2016022671A1 (https=)
ZA (1) ZA201700245B (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140044675A1 (en) 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
PT3102595T (pt) 2014-02-06 2019-01-11 Hoffmann La Roche Proteínas de fusão de interleucina-2 e suas utilizações
MA40094B1 (fr) 2014-08-06 2022-05-31 Univ Miami Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation
JP7178906B2 (ja) * 2016-05-19 2022-11-28 ザ ジェネラル ホスピタル コーポレイション ナチュラルキラー細胞および制御性Ｔ細胞の活性を強化するためのプラットフォームである、その受容体ＩＬ－２Ｒβに繋ぎ止められたインターロイキン－２
AU2017335771A1 (en) 2016-09-28 2019-02-28 Musc Foundation For Research Development Antibodies that bind interleukin-2 and uses thereof
EP3596108A4 (en) 2017-03-15 2020-12-23 Pandion Operations, Inc. TARGETED IMMUNOTOLERANCE
US10676516B2 (en) 2017-05-24 2020-06-09 Pandion Therapeutics, Inc. Targeted immunotolerance
US10174092B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
EP3746103A4 (en) 2017-12-06 2022-03-30 The Board of Trustees of the Leland Stanford Junior University PROTEINS ENGINEERED TO INCREASE A CELL'S SENSITIVITY TO IL-2
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
EP3768700A1 (en) 2018-03-23 2021-01-27 Kite Pharma, Inc. Chimeric transmembrane proteins and uses thereof
PE20210313A1 (es) * 2018-03-28 2021-02-12 Bristol Myers Squibb Co Proteinas de fusion interleucina-2/receptor alfa de interleucina-2 y metodos de uso
WO2020187848A1 (en) 2019-03-18 2020-09-24 Biontech Cell & Gene Therapies Gmbh Lnterleukin-2 receptor (il2r) and interleukin-2 (il2) variants for specific activation of immune effector cells
CN111944036B (zh) 2019-05-14 2024-09-06 上海盖浦生物科技有限公司 一种增殖免疫细胞的突变体蛋白
BR112021023345A2 (pt) 2019-05-20 2022-02-01 Pandion Operations Inc Imunotolerância com alvo em madcam
US20220227837A1 (en) * 2019-05-24 2022-07-21 Proviva Therapeutics (Hong Kong) Limited Il-2 compositions and methods of use thereof
US20210038684A1 (en) * 2019-06-11 2021-02-11 Alkermes Pharma Ireland Limited Compositions and Methods for Cancer Immunotherapy
EP3997115A4 (en) * 2019-07-12 2023-11-22 Proviva Therapeutics (Hong Kong) Limited Il-2 compositions and methods of use thereof
BR112022001320A2 (pt) * 2019-07-25 2022-04-12 Univ Chicago Composições e métodos compreendendo agentes terapêuticos ativados por protease
US20220378933A1 (en) * 2019-09-19 2022-12-01 Proviva Therapeutics (Hong Kong) Limited Il-2 compositions and methods of use thereof
BR112022007158A2 (pt) * 2019-10-18 2022-07-05 Alkermes Pharma Ireland Ltd Agentes imunomodulatórios de il-2 em combinação com inibidores do ponto de verificação imunológico
WO2021127487A2 (en) 2019-12-20 2021-06-24 Regeneron Pharmaceuticals, Inc. Novel il2 agonists and methods of use thereof
EP4107187A4 (en) 2020-02-21 2024-07-03 Pandion Operations, Inc. TISSUE-TARGETED IMMUNOTOLERANCE WITH A CD39 EFFECTOR
EP4143220A4 (en) 2020-04-30 2024-05-29 Immune Targeting Inc. COMPOSITION OF ACTIVATABLE IL2 AND METHODS OF USE
CN116194480A (zh) * 2020-08-13 2023-05-30 百时美施贵宝公司 将il-2重定向到目的靶细胞的方法
TW202317623A (zh) 2021-06-14 2023-05-01 美商再生元醫藥公司 基於il2之治療劑及其使用方法
WO2023154894A2 (en) * 2022-02-11 2023-08-17 Alkermes Pharma Ireland Limited Compositions and methods for cancer immunotherapy
US20250154216A1 (en) * 2022-02-16 2025-05-15 University Of Miami Il-2 and tl1a fusion proteins and methods of use thereof
CN114875069B (zh) * 2022-04-22 2023-09-15 四川大学 基因工程修饰的il2细胞因子的重组载体、宿主细胞及其用途
AU2024224039A1 (en) * 2023-02-22 2025-06-26 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Anti-il2ra antibodies and uses thereof
WO2025207491A1 (en) * 2024-03-25 2025-10-02 Mural Oncology, Inc. Compositions and methods for cancer immunotherapy

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ201918A (en) 1981-09-18 1987-04-30 Genentech Inc N-terminal methionyl analogues of bovine growth hormone
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
FR2619719B1 (fr) 1987-09-01 1991-05-10 Sanofi Sa Procede d'obtention d'interleukine-2 a partir de cellules eucaryotes, vecteurs necessaires a sa mise en oeuvre et lignees cellulaires hautement productrices
US5250296A (en) * 1990-11-29 1993-10-05 Takeda Chemical Industries, Ltd. Immunostimulant agent containing interleukin-2 and 5'-deoxy-5-fluorouridine
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
EP0796280B1 (en) * 1994-12-28 2003-03-26 University Of Kentucky Murine monoclonal anti-idiotype antibody 3h1
US6967092B1 (en) * 1996-10-25 2005-11-22 Mc Kearn John P Multi-functional chimeric hematopoietic receptor agonists
DE19701141C1 (de) * 1997-01-16 1998-04-09 Hoechst Ag Genkonstrukte für durch Proteasen aktivierbare Wirksubstanzen
DZ2788A1 (fr) 1998-05-15 2003-12-01 Bayer Ag Agonistes et antagonistes selectifs à IL-2.
KR20040040475A (ko) 2001-09-28 2004-05-12 가부시키가이샤 디나벡크 겐큐쇼 에피토프 결합 β２ｍ을 코드하는 포유동물 세포감염성 바이러스 벡터 및 그의 이용
US20060234205A1 (en) 2004-03-05 2006-10-19 Chiron Corporation In vitro test system for predicting patient tolerability of therapeutic agents
EP3263581B2 (en) 2005-05-17 2025-07-09 University of Connecticut Compositions and methods for immunomodulation in an organism
CN101255197B (zh) * 2008-03-28 2012-01-25 浙江海正药业股份有限公司 血清白蛋白与白介素1受体拮抗剂的融合蛋白及应用
GB0815216D0 (en) * 2008-08-21 2008-09-24 Asterion Ltd Interleukin
EP2553101A4 (en) * 2010-04-02 2013-09-04 Univ Rochester PROTEASE-ACTIVATED CYTOKINES
WO2012088383A2 (en) 2010-12-23 2012-06-28 Genentech, Inc. PILR alpha INTERACTIONS AND METHODS OF MODIFYING SAME
US9156897B2 (en) 2012-06-08 2015-10-13 Alkermes, Inc. Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide
US20140044675A1 (en) * 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
WO2014100913A1 (en) 2012-12-24 2014-07-03 Beijing Anxinhuaide Biotech. Co., Ltd Improving the half life of a therapeutic polypeptide by fusing with a trimeric scaffold protein via a spacer
MA40094B1 (fr) 2014-08-06 2022-05-31 Univ Miami Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation

Also Published As

Publication number Publication date
CN107074967A (zh) 2017-08-18
WO2016022671A1 (en) 2016-02-11
JP2017523789A (ja) 2017-08-24
KR102653758B1 (ko) 2024-04-04
ZA201700245B (en) 2024-06-26
PT3177307T (pt) 2024-09-13
EA201790063A1 (ru) 2017-06-30
FI3177307T3 (fi) 2024-10-04
EP4438621A2 (en) 2024-10-02
MA40721A (fr) 2017-06-13
MA40094A1 (fr) 2021-09-30
SG11201700706WA (en) 2017-02-27
EA202091342A2 (ru) 2020-11-30
SA517380842B1 (ar) 2021-12-26
HRP20241258T1 (hr) 2024-12-06
PH12017500042A1 (en) 2017-05-22
SMT202400414T1 (it) 2024-11-15
US20250163118A1 (en) 2025-05-22
AU2015301071C1 (en) 2020-07-02
RS65930B1 (sr) 2024-10-31
HUE068478T2 (hu) 2025-01-28
SI3177307T1 (sl) 2024-09-30
AU2022204034A1 (en) 2022-07-14
JP6723982B2 (ja) 2020-07-15
AU2015301071B2 (en) 2020-03-05
AU2020203352B2 (en) 2022-03-10
IL250007B (en) 2020-07-30
JP7272663B2 (ja) 2023-05-12
JP2021000084A (ja) 2021-01-07
IL275944A (en) 2020-08-31
MA40094B1 (fr) 2022-05-31
AU2020203352A1 (en) 2020-07-02
DK3177307T3 (da) 2024-10-07
SG10201913695PA (en) 2020-03-30
JP2023099045A (ja) 2023-07-11
NZ728042A (en) 2024-07-26
EP3177307B1 (en) 2024-07-17
CL2017000284A1 (es) 2017-11-17
EP3177307A1 (en) 2017-06-14
KR20170030646A (ko) 2017-03-17
CA2957273C (en) 2023-03-14
IL250007A0 (en) 2017-03-30
TN2017000020A1 (en) 2018-07-04
MX388977B (es) 2025-03-20
CN107074967B (zh) 2021-06-08
MA40721B1 (fr) 2024-08-30
EA035956B1 (ru) 2020-09-04
US12084483B2 (en) 2024-09-10
EA202091342A3 (ru) 2020-12-30
MX2017001062A (es) 2017-07-14
IL275944B (en) 2022-02-01
MY180831A (en) 2020-12-10
PE20170503A1 (es) 2017-05-11
BR112017001940A2 (pt) 2017-11-28
EP4438621A3 (en) 2024-12-18
US20170233448A1 (en) 2017-08-17
LT3177307T (lt) 2024-08-12
CN113912737A (zh) 2022-01-11
CA2957273A1 (en) 2016-02-11
AU2015301071A1 (en) 2017-02-02
US20230079120A1 (en) 2023-03-16
NZ766851A (en) 2024-07-26
ES2986097T3 (es) 2024-11-08

Similar Documents

Publication Publication Date Title
CO2017002166A2 (es) Proteínas de fusión de interleucina 2 / receptor de interleucina-2 alfa
MX2023013883A (es) Polipeptidos multimericos moduladores de linfocitos t y metodos para su uso.
CL2024003234A1 (es) Polipéptidos modificados y usos de los mismos.
MX2023008559A (es) Proteínas de fusión fc heterodiméricas il15/il15ra.
CO2018002450A2 (es) Proteínas de fusión de gitrl y usos de las mismas
UY40283A (es) Método para alterar una propiedad de una planta
CL2018000340A1 (es) Construcciones con un dominio sirp-alfa o sus variantes.
EA201990017A1 (ru) Антитела к миостатину и способы их применения
CL2019000729A1 (es) Proteínas de unión recombinantes y sus usos.
EA201891420A1 (ru) Антитела к миостатину, полипептиды, содержащие варианты fc-областей, и способы их применения
DOP2017000258A (es) Proteínas de fusión
BR112019023071A2 (pt) proteínas de fusão do receptor tgf-beta do tipo ii e uso das mesmas
PE20181338A1 (es) Vectores del factor viii del virus adeno-asociado, particulas viricas asociadas y formulaciones terapeuticas que los comprenden
MX382518B (es) Antigenos de citomegalovirus y su uso.
EA201791253A1 (ru) Антитела к миостатину, полипептиды, содержащие варианты fc-областей, и способы их применения
MX389878B (es) Proteinas quimericas de factor viii y usos de estas.
UY36021A (es) Proteìnas fc multimèricas
BR112018075032A2 (pt) proteínas de hemaglutinina do vírus influenza e seus uso
MX392683B (es) Composiciones farmaceuticas que comprenden variantes peptidicos y metodos para su uso.
MX380658B (es) Variantes de region fc con union mejorada de la proteina a.
CL2016000232A1 (es) Estabilización de polipéptidos que contienen fragmentos cristalizables
UY37456A (es) Inmunoglobulinas y sus usos
MX2018009524A (es) Composiciones del polipeptido de fusion tnfr: fc exentas de arginina y metodos de uso.
PE20161406A1 (es) Proteinas de fusion tatk-cdkl5, composiciones, formulaciones y uso de estas
MX2022014899A (es) Variantes y composiciones del lfa3 y sus usos.